Nanopharm’s SmartTrack: Accelerating OINDP Respiratory Drug Delivery
Revolutionize your OINDP respiratory drug delivery with Nanopharm’s SmartTrack. Accelerate development and mitigate risks through expert formulation and integrated solutions. Your pathway to success starts here.
Nanopharm: cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges
Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.
Regional Deposition in Generic Dry Powder Inhalers
Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.
Alternative regulatory path for generic Respiratory Products
Explore Nanopharm’s SmartTrack, an alternative solution for FDA approval of generic inhalation drug delivery products.
Challenges in OINDPs Achieving Q3 Equivalence
Nanopharm review the bioequivalence challenges for OINDPs by achieving Q3 structural equivalence.
